![](https://partners4access.com/wp-content/uploads/2020/05/syringe-1884784_1920-300x180.jpeg)
Blogs
Zolgensma’s ‘Day One’ access scheme – can Novartis’s early access plan succeed?
By Max Rex, Associate Consultant Email: [email protected] Zolgensma, Novartis’s blockbuster gene therapy for the treatment of spinal muscular atrophy (SMA), was officially given the green